Among patients with a new diagnosis of acute myeloid leukemia (AML), at least 10% will have disease-harboring mutations in TP53 (TP53m-AML) but up to 30% in certain subpopulations such as those with secondary AML, therapy-related AML (t-AML) or acute erythroid leukemia (and nearly all patients with the pure erythroid leukemia subtype) [2,3,4,5,6]. Here, TP53 is linked to acute myeloid leukemia.